If You Build It, Patients with Rare Cancers Will Come: A Successful Clinical Trial in Relapsed and Refractory JMML
Nana Adjoa Ben-Crentsil1, Eric Padron1
1Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida.
Abstract:
Juvenile myelomonocytic leukemia (JMML) is a rare pediatric hematologic malignancy with a high relapse rate and a poor prognosis hallmarked by RAS pathway mutations. Stieglitz and colleagues conducted a phase II clinical trial using the MEK inhibitor trametinib to treat patients with relapsed and refractory juvenile myelomonocytic leukemia and observed an objective response rate of 50% and an overall survival of 80% after 4 years. See related article by Stieglitz et al., p. 1590 (4) .
Related Concept Videos
Treatment Resistant Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Differentiation of Common Myeloid Progenitor Cells


